Merck Group

Bioburden Testing Market worth $2.59 billion by 2031 Owing To Increasing Demand for Quality Assurance and Safety Measures - Exclusive Report by Coherent Market Insights

Retrieved on: 
Thursday, February 15, 2024
Merck, Traction, Growth, ELISA, Food, Bioburden, BD (company), Safety, Mass spectrometry, Nutrient, Drink, Medium (website), SGS, Customization, Thermo Fisher Scientific, PCR, Merck Group, Polymerase chain reaction, Environmental remediation

The demand for rapid microbiological testing methods is increasing as they offer numerous advantages, including reduced testing time and improved efficiency.

Key Points: 
  • The demand for rapid microbiological testing methods is increasing as they offer numerous advantages, including reduced testing time and improved efficiency.
  • Their strong market presence and diverse product portfolio contribute to the overall growth of the bioburden testing market.
  • In summary, the bioburden testing market presents significant opportunities, with the consumables segment and aerobic count testing expected to dominate.
  • These market takeaways highlight the key factors influencing the bioburden testing market's growth and offer insights into its future direction.

Bioburden Testing Market worth $2.59 billion by 2031 Owing To Increasing Demand for Quality Assurance and Safety Measures - Exclusive Report by Coherent Market Insights

Retrieved on: 
Thursday, February 15, 2024
Merck, Traction, Growth, ELISA, Food, Bioburden, BD (company), Safety, Mass spectrometry, Nutrient, Drink, Medium (website), SGS, Customization, Thermo Fisher Scientific, PCR, Merck Group, Polymerase chain reaction, Environmental remediation

The demand for rapid microbiological testing methods is increasing as they offer numerous advantages, including reduced testing time and improved efficiency.

Key Points: 
  • The demand for rapid microbiological testing methods is increasing as they offer numerous advantages, including reduced testing time and improved efficiency.
  • Their strong market presence and diverse product portfolio contribute to the overall growth of the bioburden testing market.
  • In summary, the bioburden testing market presents significant opportunities, with the consumables segment and aerobic count testing expected to dominate.
  • These market takeaways highlight the key factors influencing the bioburden testing market's growth and offer insights into its future direction.

Global Research Antibodies Market Report 2024, Featuring Profiles of Abcam, Thermo Fisher Scientific, Cell Signaling Technology, Merck, Sino Biological & Bio-Rad - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 31, 2024
Biotechnology, Infectious Diseases, Health, Science, Research, Antigen, Growth, Bio-Rad Laboratories, ESG, Fever Dream, Therapy, HIV, Thermo Fisher Scientific, Antibody, FDA, Microscopy, IVD, Abcam, Infection, Flow cytometry, Malaria, Merck Group, Vaccine

The global market for research antibodies was valued at approximately $3.5 billion in 2022.

Key Points: 
  • The global market for research antibodies was valued at approximately $3.5 billion in 2022.
  • Among product segments, the primary antibody segment accounted for the highest market share in the global market for research antibodies in 2022.
  • The advancement of biological discoveries will result in the need for more molecular targets to be detected by their antibodies.
  • This report segments the global market for research antibodies based on type of antibody, clonality, host, major reactivities, application, end user and region.

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Retrieved on: 
Wednesday, January 24, 2024
Research, Infectious Diseases, Neurology, Cardiology, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Oncology, Hook effect, DSM-IV codes, Therapy, Monoclonal antibody, Merck Group, ADC, TCR, TRACON, HKEX, Partnership, Infection, IND, Neurocrine, Medication, Antibody, Protein, PCC, Multinational corporation, Hansoh Pharmaceutical, Vaccine

RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.

Key Points: 
  • RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.
  • The RenBiologics logo features an antibody with human-centric design elements, highlighting Biocytogen's expertise in discovering fully human antibodies; the encircled design underscores the company’s dedication to becoming a global resource of fully human antibodies to expedite the development of novel antibody-based therapeutics.
  • Biocytogen’s fully human antibody sequences were generated by proprietary RenMice strains, each engineered to lack a certain drug target gene.
  • RenMice-derived fully human antibodies can be developed into novel therapies to treat numerous cancers, inflammatory and autoimmune diseases, infectious diseases, metabolic diseases, cardiovascular diseases, and neurological diseases.

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Retrieved on: 
Tuesday, January 23, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Hook effect, DSM-IV codes, Therapy, Monoclonal antibody, Merck Group, ADC, TCR, Multimedia, TRACON, HKEX, Partnership, Infection, IND, Neurocrine, Medication, Antibody, Protein, PCC, Multinational corporation, Hansoh Pharmaceutical, Vaccine

RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.

Key Points: 
  • RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.
  • The RenBiologics logo features an antibody with human-centric design elements, highlighting Biocytogen's expertise in discovering fully human antibodies; the encircled design underscores the company’s dedication to becoming a global resource of fully human antibodies to expedite the development of novel antibody-based therapeutics.
  • RenMice®-derived fully human antibodies can be developed into novel therapies to treat numerous cancers, inflammatory and autoimmune diseases, infectious diseases, metabolic diseases, cardiovascular diseases, and neurological diseases.
  • Biocytogen offers licensing and flexible partnering models for its RenMice fully human antibody/TCR discovery platforms.

Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Retrieved on: 
Monday, January 22, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Senior, Roger Hawkins (drummer), Tamas, Patient, Carcinoma, MD, Merck Group, ADC, OS, Health care, UC, Bladder cancer, Brentuximab vedotin, ASCO, CUP, Survival, Society, READY, Quality of life, Experiment (probability theory), Safety, PRO, Merck Serono, Toxicity, Doctor of Philosophy, BMI, Merck, BSC, Czech, Pharmaceutical industry

Data include real-world studies that confirm median overall survival (OS) of approximately 30 months in patients without progression after first-line chemotherapy.

Key Points: 
  • Data include real-world studies that confirm median overall survival (OS) of approximately 30 months in patients without progression after first-line chemotherapy.
  • These and other analyses will be presented at the 2024 American Society of Clinical Oncology’s annual Genitourinary Cancers Symposium, January 25-27, in San Francisco.
  • “Avelumab in the first-line maintenance setting is a standard of care for patients with locally advanced or metastatic bladder cancer, with a well-established efficacy and safety profile and supported by years of real-world experience.
  • READY CUP Italy Real-World Study: The prospective, noninterventional compassionate use program (CUP) provided Italian patients with locally advanced or metastatic UC early access to BAVENCIO first-line maintenance before reimbursement.

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

Retrieved on: 
Thursday, January 25, 2024
BIA, BGF, Biotechnology, Ion channel, COVID-19, Cytomegalovirus, Methamphetamine, UBS, Therapy, Asthma, Meetup, Disease, Venture, Innovation, ADHD, Safety, Frontotemporal dementia, Eurosport 1, AstraZeneca, Cocaine, CMV, Chair, COPD, Infection, Investment, LifeArc, AbCellera, Bose, Patient, Associate, G protein-coupled receptor, Partnership, Innovate UK, Merck Group, Ecosystem, PwC, FDA, System, Chronic pain, Clinical trial, News, Pharmaceutical industry

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.

Key Points: 
  • LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.
  • We have expanded our investment team, adding two new members and further strengthened our Early Ventures Investment Committee through the appointment of a new Chair and new independent member.
  • Jon joined us from M Ventures' biotechnology investment team and previously was an associate within the healthcare investment banking team at UBS, after starting his career as a doctor.
  • In addition, Clare Terlouw, Head of LifeArc Ventures, was re-elected to the BioIndustry Association (BIA) Board of Directors for the third time.

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

Retrieved on: 
Thursday, January 25, 2024
BIA, BGF, Biotechnology, Ion channel, COVID-19, Cytomegalovirus, Methamphetamine, UBS, Therapy, Asthma, Meetup, Disease, Venture, Innovation, ADHD, Safety, Frontotemporal dementia, Eurosport 1, AstraZeneca, Cocaine, CMV, Chair, COPD, Infection, Investment, LifeArc, AbCellera, Bose, Patient, Associate, G protein-coupled receptor, Partnership, Innovate UK, Merck Group, Ecosystem, PwC, FDA, System, Chronic pain, Clinical trial, News, Pharmaceutical industry

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.

Key Points: 
  • LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.
  • We have expanded our investment team, adding two new members and further strengthened our Early Ventures Investment Committee through the appointment of a new Chair and new independent member.
  • Jon joined us from M Ventures' biotechnology investment team and previously was an associate within the healthcare investment banking team at UBS, after starting his career as a doctor.
  • In addition, Clare Terlouw, Head of LifeArc Ventures, was re-elected to the BioIndustry Association (BIA) Board of Directors for the third time.

USD 1.76 billion growth expected in Lithium-Sulfur Battery Market between 2022 and 2027, Analysing growth in Europe - 17,000+ Technavio Research Reports

Retrieved on: 
Tuesday, January 23, 2024
Lithium, Electrolyte, EVS, Aviation, Merck Group, Harmful, Gravity battery, Cyclic permutation, Lithium battery, Growth, App Store (iOS/iPadOS), Energy density, USD, EV, Gesellschaft mit beschränkter Haftung, Longevity, LG Chem, CIC

NEW YORK, Jan. 22, 2024 /PRNewswire/ -- The lithium-sulfur battery market size is expected to grow by USD 1.76 billion from 2022 to 2027, according to Technavio.

Key Points: 
  • NEW YORK, Jan. 22, 2024 /PRNewswire/ -- The lithium-sulfur battery market size is expected to grow by USD 1.76 billion from 2022 to 2027, according to Technavio.
  • In addition, the growth momentum of the market will progress at a CAGR of 33.06% during the forecast period.
  • The US, a major contributor to North America's Li-S battery market revenue, experiences high drone and EV adoption, necessitating batteries with extended runtime.
  • The train battery market is estimated to grow at a CAGR of 5.45% between 2022 and 2027.

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Retrieved on: 
Tuesday, January 16, 2024
DISCO, Stanford University, Patient, Sofinnova, Therapy, Research, Colorectal cancer, Umoja, University, Map, COYA, Pfizer, Drug discovery, EVP, Roche, Spacecraft, SCLC, ETH, BMS, Protein, CDO, Genome, Bayer, Doctor of Philosophy, Proteomics, Merck Group, Carcinoma

Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.

Key Points: 
  • Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.
  • COLOGNE, Germany and ZURICH, Jan. 16, 2024 /PRNewswire/ -- DISCO Pharmaceuticals ("DISCO"), a specialist biotech unlocking the surfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth today.
  • The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed financing of EUR 20 million and is backed by a world leading investor syndicate, including Sofinnova Partners, which led the round, Panakes Partners, M Ventures and AbbVie Ventures.
  • Roman Thomas, Founder and Chief Executive Officer, at DISCO Pharmaceuticals, said: "Today, we are launching DISCO Pharmaceuticals and its breakthrough technology after a decade of research by our exceptional team.